NCT07594548
Futibatinib With Paclitaxel and Ramucirumab for the Treatment of Locally Advanced or Unresectable Gastric, Gastroesophageal Junction, or Esophageal Adenocarcinoma
Free. We email you which fields changed when ClinicalTrials.gov updates this record.
Record History
All 3 versions: 3 with changes below. See every version on ClinicalTrials.gov ↗
- Notable Recruitment opened
- Start date changed from estimate of Sep 9, 2027 to Nov 10, 2026
- Site details revised at 2 of 2 sites
- Notable Eligibility criteria expanded, about 59 words
- Secondary endpoints: details revised at 4 of 5 entries
- Study description revised
- Site contacts updated at 2 of 2 sites
- Study First Submitted
- Notable: the plan changed
Endpoints
Primary
Secondary (5)
Arms and interventions
Patients receive ramucirumab IV over 30-60 minutes on days 1 and 15 of each cycle, paclitaxel IV over 60 minutes on days 1, 8 and 15 of each cycle, and futibatinib PO QD on days 8-28 of cycle 1 and days 1-28 of subsequent cycles. Cycles repeat every 28 days in the absence of disease progression or unacceptable toxicity. Patients undergo CT or MRI, and optional blood and urine sample collection throughout the study.
Procedures: Biospecimen Collection, Computed Tomography, Magnetic Resonance Imaging
Drugs: Futibatinib, Paclitaxel
Biologicals: Ramucirumab
Sites
2 sites in 1 country